SARS-CoV-2/COVID-19 Testing: The Tower of Babel
Main Article Content
Keywords
COVID-19, SARS-CoV-2, Pandemic, Molecular Diagnostic Techniques, Rapid Antigen Test, Pooling Test, Predictive Value of Tests, Public Health Surveillance, Screening
Abstract
Background and aim: Testing represents one of the main pillars of public health response to SARS-CoV-2/COVID-19 pandemic. This paper shows how accuracy and utility of testing programs depend not just on the type of tests, but on the context as well.
Methods: We describe the testing methods that have been developed and the possible testing strategies; then, we focus on two possible methods of population-wide testing, i.e., pooled testing and testing with rapid antigen tests. We show the accuracy of split-pooling method and how, in different pre-test probability scenarios, the positive and negative predictive values vary using rapid antigen tests.
Results: Split-pooling, followed by retesting of negative results, shows a higher sensitivity than individual testing and requires fewer tests. In case of low pre-test probability, a negative result with antigen test could allow to rule out the infection, while, in case of a positive result, a confirmatory molecular test would be necessary.
Conclusions: Test performance alone is not enough to properly choose which test to use; goals and context of the testing program are essential. We advocate the use of pooled strategies when planning population-wide screening, and the weekly use of rapid tests for close periodic monitoring in low-prevalence populations.
Downloads
References
2. Pasquarella C, Colucci ME, Bizzarro A, et al. Detection of SARS-CoV-2 on hospital surfaces. Acta Biomed. 2020;91(9-S):76-78.
3. European Centre for Disease Prevention and Control. Population-wide testing of SARS-CoV-2: country experiences and potential approaches in the EU/EEA and the UK Stockholm: ECDC; 2020
4. Food & Drug Administration. Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised). May 11, 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised (accessed Nov 6, 2020)
5. European Commission. COMMUNICATION FROM THE COMMISSION: Guidelines on COVID-19 in vitro diagnostic tests and their performance. April 15, 2020. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52020XC0415(04) (accessed Nov 6, 2020)
6. European Commission. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX%3A31998L0079 October 27, 1998 (accessed Nov 6, 2020)
7. Centers for Disease Control and Prevention. Interim Guidance for Rapid Antigen Testing for SARS-CoV-2. September 4, 2020. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html (accessed Nov 6, 2020)
8. Istituto Superiore di Sanità. Report ISS 29 maggio. May 29, 2020. https://www.epicentro.iss.it/coronavirus/pdf/rapporto-covid-19-11-2020.pdf (accessed Nov 6, 2020)
9. Riccò M, Ferraro P, Gualerzi G, et al. Point-of-Care Diagnostic Tests for Detecting SARS-CoV-2 Antibodies: A Systematic Review and Meta-Analysis of Real-World Data. J Clin Med. 2020;9(5):1515.
10. Veronesi L, Colucci ME, Pasquarella C, et al. Virological surveillance of SARS-CoV-2 in an Italian northern area: comparison of Real Time RT PCR cycle threshold (Ct) values in three epidemic periods. Acta Biomed. 2020;91(9-S):19-21.
11. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020;323(22):2249–2251.
12. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med. 2020 Aug 18;173(4):262-267.
13. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. N Engl J Med. 2020;10.1056/NEJMc2016359.
14. Food & Drug Administration. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing. August 15, 2020 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-yale-school-public-health (accessed Nov 6, 2020)
15. SalivaDirect https://publichealth.yale.edu/salivadirect/ (accessed Nov 6, 2020)
16. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, et al. Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2020 Aug 26;8:CD013705.
17. Piltch-Loeb, R.N., Jeong, K.Y., Lin, K., Kraemer, J.D., Stoto, M.A. Interpreting COVID-19 test results in clinical settings: it depends! Journal of the American Board of Family Medicine, published online ahead of print on October 9, 2020.
18. Stoto M.A., Wynia, M.K. Assessing Morbidity and Mortality Associated with the COVID-19 Pandemic: A Case Study Illustrating the Need for the Recommendations in this Report. In National Academies of Sciences, Engineering, and Medicine, A Framework for Assessing Mortality and Morbidity After Large-Scale Disasters, 2020. (https://www.nap.edu/read/25863/chapter/11)
19. Piltch-Loeb R, Kraemer J, Lin KW, Stoto MA. Public Health Surveillance for Zika Virus: Data Interpretation and Report Validity. Am J Public Health. 2018 Oct;108(10):1358-1362.
20. Rosenberg ES, Hall EW, Rosenthal EM, et al. Monitoring Coronavirus Disease 2019 (COVID-19) Through Trends in Influenza-like Illness, Laboratory-confirmed Influenza, and COVID-19—New York State, Excluding New York City, 1 January 2020–12 April 2020. Clin Infect Dis. 2020; 4-7.
21. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020;382(24):2302-2315.
22. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313-319.
23. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda et al. ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020 Aug 22;396(10250):535-544.
24. ISTAT. Primi risultati dell’indagine di sieroprevalenza sul SARS-CoV-2. Italian Institute of Statistics. August 2020. https://www.istat.it/it/files/2020/08/ReportPrimiRisultatiIndagineSiero.pdf
(accessed October 30, 2020)
25. Perico L, Tomasoni S, Peracchi T, Perna A, Pezzotta A, Remuzzi G, Benigni A. COVID-19 and lombardy: TESTing the impact of the first wave of the pandemic. EBioMedicine. 2020 Oct 22;61:103069.
26. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. Lancet. 2020;6736(20):1-10.
27. Cox, R.J., Brokstad, K.A. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol 20, 581–582 (2020).
28. Walke HT, Honein MA, Redfield RR. Preventing and Responding to COVID-19 on College Campuses. JAMA. 2020;324(17):1727-1728
29. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. N Engl J Med. 2020 Sep 30.
30. Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States. JAMA Network Open 2020; 3(7): e2016818.
31. Weis S, Sherag A, Baier M, Kiehntopf M, Kamradt Y, Kolanos S, et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak - the CoNAN study. medRxiv 2020.07.15.20154112; doi: https://doi.org/10.1101/2020.07.15.20154112
32. European Center for Disease Control. Diagnostic testing and screening for SARS-CoV-2. June 11, 2020 Stockholm: ECDC; 2020 https://www.ecdc.europa.eu/en/covid-19/latest-evidence/diagnostic-testing (accessed Nov 6, 2020)
33. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. N Engl J Med. 2020 May 28;382(22):2158-2160.
34. European Center for Disease Control. COVID-19 in children and the role of school settings in COVID-19 transmission. August 6, 2020. Stockholm: ECDC; 2020.
35. Lavezzo, E., Franchin, E., Ciavarella, C. et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’. Nature 584, 425–429 (2020).
36. European Centre for Disease Prevention and Control. Methodology for estimating point prevalence of SARSCoV-2 infection by pooled RT-PCR testing. Stockholm: ECDC; 2020.
37. Saarland University. Virologists show that sample pooling can massively increase coronavirus testing capacity. April 28, 2020. https://www.eurekalert.org/pub_releases/2020-04/su-vst042820.php (accessed October 30, 2020)
38. Dorfman R. The detection of defective numbers of large populations. Ann Math Stat.
1943;14:436-440
39. Litvak E, Tu XM, Pagano M. Screening for the Presence of a Disease by Pooling Sera Samples. Journal of the American Statistical Association 1994:89(426):424-434.
40. Mahase E. Covid-19: Universities roll out pooled testing of students in bid to keep campuses open BMJ 2020; 370 :m3789
41. Carlson C. How will Syracuse University test 20,000 students for coronavirus? By pooling their saliva. July 08, 2020 https://www.syracuse.com/coronavirus/2020/07/how-will-syracuse-university-test-20000-students-for-coronavirus-by-pooling-their-saliva.html (accessed October 30, 2020)
42. LOMT - Laboratory Optimizer for Mass Testing https://lomt.jetware.org/ (accessed October 30, 2020)
43. Results Manager. https://www.results-manager.com/ (accessed October 30, 2020)
44. Guglielmi G. Fast coronavirus tests: what they can and can’t do. Nature 585, 496-498 (2020)
45. Scondotto S, Bisceglia L, Bauleo L, et al. Associazione Italiana di Epidemiologia. COVID-19: strumenti per decisioni politiche fondate sulle prove. October 28, 2020. https://www.epidemiologia.it/wp-content/uploads/2020/10/COVID-19_strumenti-per-decisioni-politiche-fondate-sulle-prove_AIE.pdf (accessed November 6, 2020)
46. Watson J. Interpreting a covid-19 test result. BMJ 2020;369:m1808
47. INAIL. Test di laboratorio per SARS-CoV-2e loro uso in sanità pubblica. https://www.inail.it/cs/internet/docs/alg-test-laboratorio-sar-covid.pdf (accessed October 30, 2020)
48. https://lab24.ilsole24ore.com/coronavirus/#box_6
Article Sidebar
Article Details
How to Cite
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.